Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Leon Berard
University of Iowa
M.D. Anderson Cancer Center
Eli Lilly and Company
Hoffmann-La Roche
Massachusetts General Hospital
Eli Lilly and Company
Sarcoma Oncology Research Center, LLC
Bambino Gesù Hospital and Research Institute
Cybrexa Therapeutics